Clinical Trial Update: Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating sunitinib (SU011248) in male patients with relapsed or cisplatin-refractory germ cell cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Testicular Germ Cell Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Relapsed or Cisplatin-Refractory Germ Cell Cancer | Phase 2 | Status: COMPLETED